pravastatin has been researched along with Fetal Growth Retardation in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Arena, V; De Carolis, S; Dell'Aquila, M; Di Stasio, E; Ferrazzani, S; Fruci, S; Gallini, F; Lanzone, A; Moresi, S; Salvi, S | 1 |
| Alijotas-Reig, J; Bonacina, E; Carreras, E; Ferrer-Oliveras, R; Garcia-Manau, P; Mendoza, M; Rodo, C | 1 |
| Contento, G; Girardi, G; Jurisic, A; Jurisic, Z; Lefkou, E; Pombo, J; Varoudi, K | 1 |
| Girardi, G; Jurisic, A; Jurisic, Z; Lefkou, E | 1 |
| Heinonen, T; Huttala, O; Laivuori, H; Tihtonen, K; Toimela, T; Uotila, J; Virtanen, A | 1 |
| Asher-Landsberg, J; Gamzu, R; Kliger, C; Kupferminc, MJ; Rimon, E; Skornick-Rapaport, A; Yogev, Y | 1 |
| Girardi, G; Jurisic, A; Jurisic, Z; Lefkou, E; Pombo, J | 1 |
| Chimini, JS; da Silva, MLS; Dias-Junior, CA; Possomato-Vieira, JS | 1 |
| Chapman, KE; Holmes, MC; Miller, MR; Moran, CM; Noble, J; Rog-Zielinska, EA; Seckl, JR; Tesic, D; Thomson, A; Wyrwoll, CS | 1 |
9 other study(ies) available for pravastatin and Fetal Growth Retardation
| Article | Year |
|---|---|
Pravastatin for severe preeclampsia with growth restriction: Placental findings and infant follow-up.
Topics: Female; Fetal Growth Retardation; Follow-Up Studies; Humans; Infant; Infant, Newborn; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Pregnancy Outcome | 2023 |
Evaluating the Effect of Pravastatin in Early-Onset Fetal Growth Restriction: A Nonrandomized and Historically Controlled Pilot Study.
Topics: Biomarkers; Birth Weight; Female; Fetal Development; Fetal Growth Retardation; Historically Controlled Study; Humans; Infant, Newborn; Pilot Projects; Placenta Growth Factor; Pravastatin; Pregnancy; Pregnancy Outcome; Ultrasonography, Doppler; Ultrasonography, Prenatal; Vascular Endothelial Growth Factor Receptor-1 | 2021 |
Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fetal Growth Retardation; Hemodynamics; Heparin, Low-Molecular-Weight; Humans; Mice; Mice, Inbred C57BL; Nitric Oxide; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2020 |
Pravastatin plus L-arginine prevents adverse pregnancy outcomes in women with uteroplacental vascular dysfunction.
Topics: Adult; Arginine; Drug Therapy, Combination; Female; Fetal Growth Retardation; Hemodynamics; Humans; Live Birth; Pilot Projects; Placental Circulation; Placental Insufficiency; Pravastatin; Pre-Eclampsia; Pregnancy; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Ultrasonography, Prenatal | 2021 |
Angiogenic Effect of Pravastatin Alone and with Sera from Healthy and Complicated Pregnancies Studied by in vitro Vasculogenesis/Angiogenesis Assay.
Topics: Adult; Angiogenesis Inhibitors; Angiogenic Proteins; Case-Control Studies; Cells, Cultured; Coculture Techniques; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Neovascularization, Physiologic; Pravastatin; Pre-Eclampsia; Pregnancy; Stromal Cells; Young Adult | 2021 |
Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study.
Topics: Abruptio Placentae; Aspirin; Female; Fetal Growth Retardation; Heparin, Low-Molecular-Weight; Humans; Pilot Projects; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Retrospective Studies; Stillbirth | 2022 |
Pravastatin and-L-arginine combination improves umbilical artery blood flow and neonatal outcomes in dichorionic twin pregnancies through an nitric oxide-dependent vasorelaxant effect.
Topics: Adult; Animals; Arginine; Blood Flow Velocity; Drug Combinations; Female; Fetal Growth Retardation; Gestational Age; Humans; In Vitro Techniques; Infant, Newborn; Infant, Premature; Live Birth; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase Type III; Pilot Projects; Pravastatin; Pregnancy; Pregnancy, Twin; Premature Birth; Treatment Outcome; Twins, Dizygotic; Ultrasonography, Prenatal; Umbilical Arteries; Vascular Resistance; Vasodilation; Vasodilator Agents | 2018 |
Placental nitric oxide formation and endothelium-dependent vasodilation underlie pravastatin effects against angiogenic imbalance, hypertension in pregnancy and intrauterine growth restriction.
Topics: Animals; Blood Pressure; Disease Models, Animal; Endothelium, Vascular; Female; Fetal Growth Retardation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pregnancy-Induced; Neovascularization, Physiologic; Nitric Oxide; Oxidative Stress; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Rats; Rats, Wistar; Vasodilation | 2019 |
Pravastatin ameliorates placental vascular defects, fetal growth, and cardiac function in a model of glucocorticoid excess.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Animals; Anticholesteremic Agents; Female; Fetal Growth Retardation; Glucocorticoids; Heart Diseases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Placenta Diseases; Pravastatin; Pregnancy; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2016 |